


Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Please cancel claim 11 without prejudice.

Please add new claims 19 and 20.

1. (Previously Presented) A compound of the formula (I)



wherein

a is an integer selected from 0 to 2;

R^{10} is selected from the group consisting of C_{1-6} alkyl, aryl, C_3-C_8 cycloalkyl, aralkyl, heteroaryl, heteroaryl- C_{1-6} alkyl, heterocycloalkyl and heterocycloalkyl- C_{1-6} alkyl; wherein the aryl, cycloalkyl, aralkyl, heteroaryl or heterocycloalkyl group may be optionally substituted with one to four substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, halogenated C_{1-6} alkyl, C_{1-6} alkoxy, halogenated C_{1-6} alkoxy, nitro, cyano, amino, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, C_{1-6}

alkylsulfonyl, C_1 -alkoxysulfonyl or halogenated C_1 -alkylsulfonyl;

x is selected from the group consisting of CH and $C(C_1-C_6alkyl)$;

m is an integer selected from 0 and 1;

L^1 is selected from the group consisting of C_1-C_6alkyl ;

Y^1 is selected from the group consisting of $C(O)$ and $C(S)$;

R^1 and R^2 are each independently selected from the group consisting of hydrogen, C_1-C_6alkyl , aryl, aralkyl, $C_3-C_8cycloalkyl$, $C_3-C_8cycloalkyl-C_1-C_6alkyl$, heteroaryl, heteroaryl- C_1-C_6alkyl , heterocycloalkyl and heterocycloalkyl- C_1-C_6alkyl ; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, C_1-C_6alkyl , $C_1-C_6alkoxy$, halogenated C_1-C_6alkyl , halogenated $C_1-C_6alkoxy$, nitro, cyano, amino, $C_1-C_4alkylamino$, di(C_1-C_4alkyl)amino, heteroaryl or heterocycloalkyl;

alternatively, R^1 and R^2 may be taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl;

Y^2 is selected from the group consisting of CH_2 , $C(O)$, $C(S)$ and SO_2 ;

R^3 is selected from the group consisting of aryl and aralkyl; wherein the aryl or aralkyl may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, C_1-C_6alkyl , $C_1-C_6alkoxy$, halogenated C_1-C_6alkyl , halogenated $C_1-C_6alkoxy$, nitro, cyano, amino, $C_1-C_4alkylamino$, di(C_1-C_4alkyl)amino or $-(L^2)_n-R^4$;

n is an integer selected from 0 and 1;
L² is selected from the group consisting of C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl, C(O), C(S), SO₂ and (A)₀₋₁-Q-(B)₀₋₁;
where A and B are each independently selected from C₁-C₆alkyl, C₂-C₆alkenyl and C₂-C₆alkynyl;
where Q is selected from the group consisting of NR⁵, O and S;
where R⁵ is selected from the group consisting of hydrogen, C₁-C₆alkyl, aryl, aralkyl, C₃₋₈cycloalkyl, heteroaryl, heterocycloalkyl, C(O)-C₁-C₆alkyl, C(O)-aryl, C(O)-aralkyl, C(O)-heteroaryl, C(O)-heterocycloalkyl, SO₂-C₁-C₆alkyl, SO₂-aryl, SO₂-aralkyl, SO₂-heteroaryl, SO₂-heterocycloalkyl and -CHR⁶R⁷;
wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, C₁-C₆alkyl, C₁-C₆ alkoxy, halogenatedC₁-C₆alkyl, halogenatedC₁-C₆alkoxy, nitro, cyano, amino, C₁-C₄alkylamino or di(C₁-C₄alkyl)amino;
where R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, C₁₋₆alkyl, aryl, aralkyl, C₃₋₈cycloalkyl, heteroaryl, heterocycloalkyl, C(O)-C₁₋₆alkyl, C(O)aryl, C(O)-C₃₋₈cycloalkyl, C(O)-heteroaryl and C(O)-heterocycloalkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, C₁-C₆alkyl, C₁-C₆ alkoxy, halogenatedC₁-C₆alkyl, halogenatedC₁-C₆alkoxy, nitro, cyano, amino, C₁-C₄alkylamino or di(C₁-C₄alkyl)amino;

R^4 is selected from the group consisting of aryl, aralkyl, C_3 - C_8 cycloalkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogenated C_1 - C_6 alkyl, halogenated C_1 - C_6 alkoxy, nitro, cyano, amino, C_1 - C_4 alkylamino or di(C_1 - C_4 alkyl)amino;


provided that when a is 0; X is CH ; m is 1; L^1 is CH_2 ; R^3 is phenyl; n is 0; and R^4 is phenyl, wherein the phenyl group may be optionally substituted with one substituent selected from halogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogenated C_1 - C_6 alkyl, halogenated C_1 - C_6 alkoxy, nitro, cyano, amino, C_1 - C_4 alkylamino or di(C_1 - C_4 alkyl)amino, and wherein the R^4 group is bonded to the R^3 group in the para position;

then R^1 and R^2 are each independently selected from the group consisting of hydrogen, C_3 - C_6 alkyl, aryl, aralkyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_6 alkyl, heteroaryl, heteroaryl- C_1 - C_6 alkyl, heterocycloalkyl and heterocycloalkyl- C_1 - C_6 alkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, halogenated C_1 - C_6 alkyl, halogenated C_1 - C_6 alkoxy, nitro, cyano, amino, C_1 - C_4 alkylamino, di(C_1 - C_4 alkyl)amino, heteroaryl or heterocycloalkyl;

alternatively, R^1 and R^2 may be taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl;

and pharmaceutically acceptable salts thereof.

2. (Previously Presented) A compound as in Claim 1 of the formula



wherein

a is 0 to 1;

R¹⁰ is selected from the group consisting of C₁-C₄alkyl and aralkyl;

X is selected from the group consisting of CH and C(methyl);

m is an integer selected from 0 or 1;

L¹ is selected from the group consisting of C₁-C₄ alkyl;

Y¹ is C(O);

R¹ and R² are each independently selected from the group consisting of hydrogen, C₁₋₄alkyl, aryl, aralkyl, C₃₋₈cycloalkyl-C₁-C₄alkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl or heteroaryl may be optionally substituted with one to two substituents independently selected from halogen, hydroxy,

C_1 - C_4 alkyl, C_1 - C_4 alkoxy, trifluoromethyl, trifluoromethoxy, C_1 - C_4 alkylamino, di(C_1 - C_4 alkyl)amino or heterocycloalkyl;

alternatively, R^1 and R^2 may be taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl; Y^2 is $C(O)$;

R^3 is selected from the group consisting of aryl; wherein the aryl may be optionally substituted with one to two substituents independently selected from C_1 - C_4 alkyl, trifluoromethyl or $-(L^2)_n-R^4$;

n is an integer selected from 0 or 1;

L^2 is selected from the group consisting of C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl and $(A)_{0-1}-Q-(B)_{0-1}$;

where A and B are each independently selected from C_1 - C_4 alkyl;

where Q is selected from the group consisting of NR^5 , O and S ;

where R^5 is selected from the group consisting of hydrogen, C_1 - C_4 alkyl, $C(O)-C_1-C_6$ alkyl, $C(O)$ -aryl, $C(O)$ -aralkyl, $C(O)$ -heteroaryl, $C(O)$ -heterocycloalkyl and $-CHR^6R^7$; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one to two substituents independently selected from halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, amino, C_1 - C_4 alkylamino or di(C_1 - C_4 alkyl)amino;

where R^6 and R^7 are each independently selected from the group consisting of hydrogen, C_1 - C_4 alkyl, aryl, aralkyl, C_3 -cycloalkyl, heteroaryl, heterocycloalkyl, $C(O)-C_1-C_6$ alkyl,

C(O)aryl, C(O)-C₃₋₈cycloalkyl, C(O)-heteroaryl and C(O)-heterocycloalkyl; wherein the aryl, aralkyl, cycloalkyl, heteroaryl or heterocycloalkyl may be optionally substituted with one to two substituents independently selected from halogen, hydroxy, C₁-C₄alkyl, C₁-C₄alkoxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, amino, C₁-C₄alkylamino or di(C₁-C₄alkyl)amino;

R⁴ is selected from the group consisting of aryl, heteroaryl and heterocycloalkyl; wherein the aryl group may be optionally substituted with one to two substituents independently selected from halogen, hydroxy, C₁-C₄alkyl, C₁₋₄alkoxy, trifluoromethyl or amino;

provided that when a is 0; X is CH; m is 1; L¹ is CH₂; R³ is phenyl; n is 0; and R⁴ is phenyl, wherein the phenyl group may be optionally substituted with one substituent selected from halogen, hydroxy, C₁-C₄alkyl, C₁-C₄alkoxy, trifluoromethyl or amino, and wherein the R⁴ group is bonded to the R³ group in the para position;

then R¹ and R² are each independently selected from the group consisting of hydrogen, C₂₋₄alkyl, aryl, aralkyl, C₃₋₈cycloalkyl-C₁-C₄alkyl, heteroaryl and heterocycloalkyl; wherein the aryl, aralkyl or heteroaryl may be optionally substituted with one to two substituents independently selected from halogen, hydroxy, C₁-C₄alkyl, C₁-C₄alkoxy, trifluoromethyl, trifluoromethoxy, C₁-C₄alkylamino, di(C₁-C₄alkyl)amino or heterocycloalkyl;

alternatively, R¹ and R² may be taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group

consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl;

and pharmaceutically acceptable salts thereof.

3. (Previously Presented) A compound as in Claim 2 wherein

X is CH;

m is 1;

R¹ is selected from the group consisting of hydrogen and C₁-C₄alkyl;

R² is selected from the group consisting of C₁-C₄alkyl, aryl, aralkyl, C₂-C₆cycloalkyl-C₁-C₄alkyl and heteroaryl; wherein the aryl or aralkyl may be optionally substituted with one to two substituents independently selected from halogen, hydroxy, C₁-C₄alkyl, C₁-C₄alkoxy, trifluoromethyl, trifluoromethoxy, di(C₁-C₄alkyl)amino or heterocycloalkyl;

alternatively, R¹ and R² may be taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group consisting of pyrrolidinyl, piperidinyl and morpholinyl;

R³ is selected from the group consisting of aryl; wherein the aryl may be optionally substituted with a substituent selected from C₁-C₄alkyl or trifluoromethyl;

L¹ is selected from the group consisting of C₁-C₄alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, NH-C₁-C₄alkyl, C₁-C₄alkyl-N(C₁-C₄alkyl)-C₁-C₄alkyl and C₁-C₄alkyl-N(C(O)C₁-C₄alkyl)-C₁-C₄alkyl;

provided that when a is 0; X is CH; L¹ is CH₂; R³ is phenyl; n is 0; and R⁴ is phenyl, wherein the phenyl group may be optionally substituted with one substituent selected from

halogen, hydroxy, C₁-C₄alkyl, C₁-C₄alkoxy, trifluoromethyl or amino, and wherein the R¹ group is bonded to the R³ group in the para position;

then R¹ is selected from the group consisting of hydrogen and C₂-C₄alkyl;

R² is selected from the group consisting of C₂-C₄alkyl, aryl, aralkyl, C₃-C₈cycloalkyl-C₁-C₄alkyl and heteroaryl; wherein the aryl or aralkyl may be optionally substituted with one to two substituents independently selected from halogen, hydroxy, C₁-C₄alkyl, C₁-C₄alkoxy, trifluoromethyl, trifluoromethoxy, di(C₁-C₄alkyl)amino or heterocycloalkyl;

alternatively, R¹ and R² are taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group consisting of pyrrolidinyl, piperidinyl and morpholinyl;

and pharmaceutically acceptable salts thereof.

4. (Previously Presented) A compound as in Claim 3 wherein R¹⁰ is selected from the group consisting of methyl and benzyl;


L¹ is selected from the group consisting of CH₂ and CH₂CH₂;




R² is selected from the group consisting of -CH₂- (3-trifluoromethylphenyl), -CH₂-cyclohexyl, -CH₂- (3,5-dimethoxyphenyl), -CH₂- (4-trifluoromethylphenyl), -CH₂- (3,5-ditrifluoromethylphenyl), 3-trifluoromethoxyphenyl, -CH₂- (4-dimethylaminophenyl), phenyl, benzyl, 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-hydroxyphenyl, 4-dimethylamino-phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-pyridyl-methyl, 4-morpholinyl-phenyl, 4-piperidinyl-

phenyl, methyl, isopropyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-quinolinyl, 6-quinolinyl, and 8-quinolinyl;

alternatively, R¹ and R² are taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group consisting of pyrrolidinyl, piperidinyl and morpholinyl;

R³ is selected from the group consisting of phenyl, methylphenyl and trifluoromethylphenyl;

L² is selected from the group consisting of 2-, 3-

, 4-, 5-, 2-, 3-, 2-, 3-, 4-, 2-, 3-, 4-, 2-CH₂CH₂, 3-CH₂-CH₂, 4-CH₂-CH₂, NH-CH₂, CH₂-N(CH₃)-CH₂, CH₂-N(CH₃)-CH₂CH₂, CH₂-N(C(O)CH₃)-CH₂ and CH₂-N(C(O)CH₃)-CH₂CH₂;

R⁴ is selected from the group consisting of phenyl, 1-naphthyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-hydroxyphenyl, 2-methylphenyl, 3-aminophenyl, 4-methoxyphenyl, 4-chlorophenyl, 2-thienyl, 3-thienyl, 3,5-di(trifluoromethyl)-phenyl, 1-imidazolyl, 2-benzimidazolyl, 1-pyrrolidinyl, 2-furyl and 2-tetrahydrafuryl;


provided that when a is 0; X is CH; L¹ is CH₂; R³ is phenyl; n is 0; and R⁴ is phenyl, 4-chlorophenyl, 3-hydroxyphenyl, 2-methylphenyl, 4-methoxyphenyl or 3-aminophenyl; and wherein the R⁴ group is bonded to the R³ group in the para position;

then R¹ is selected from the group consisting of hydrogen and C₂₋₄alkyl;

R^2 is selected from the group consisting of $-CH_2-(3$ -trifluoromethylphenyl), $-CH_2$ -cyclohexyl, $-CH_2-(3,5$ -dimethoxyphenyl), $-CH_2-(4$ -trifluoromethylphenyl), $-CH_2-(3,5$ -ditrifluoromethylphenyl), 3-trifluoromethoxyphenyl, $-CH_2-(4$ -dimethylaminophenyl), phenyl, benzyl, 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 4-hydroxyphenyl, 4-dimethylamino-phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 4-pyridyl-methyl, 4-morpholinyl-phenyl, 4-piperidinyl-phenyl, isopropyl, 4-methoxyphenyl, 4-trifluoromethylphenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-quinolinyl, 6-quinolinyl, and 8-quinolinyl;

alternatively, R^1 and R^2 are taken together with the nitrogen atom to which they are bound to form a five to six membered monocyclic ring structure selected from the group consisting of pyrrolidinyl, piperidinyl and morpholinyl; and pharmaceutically acceptable salts thereof.


5. (Original) A compound as in Claim 4 of the formula











wherein

R^2 is selected from the group consisting of $-CH_2-(3$ -trifluoromethylphenyl), $-CH_2$ -cyclohexyl, $-CH_2-(3,5$ -dimethoxyphenyl), $-CH_2-(4$ -trifluoromethylphenyl), $-CH_2-(3,5$ -

ditrifluoromethylphenyl), -CH₂-(4-dimethylaminophenyl), phenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-hydroxyphenyl, 4-methoxyphenyl, benzyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-quinolinyl, 6-quinolinyl, 8-quinolinyl, 4-(dimethylamino)-phenyl, 4-morpholinyl-phenyl, 4-pyridyl-methyl, and 4-piperidinyl-phenyl;

L² is selected from the group consisting of 2-, 3-

, 4-, 5-, 2-, 3-, 4-, 2-, 3-, 2-CH₂CH₂, 3-CH₂-CH₂, 4-CH₂-CH₂, NH-CH₂, 4-(CH₂-N(CH₃)-CH₂), 4-(CH₂-N(CH₃)-CH₂CH₂), 4-(CH₂-N(C(O)CH₃)-CH₂) and 4-(CH₂-N(C(O)CH₃)-CH₂);

R⁴ is selected from the group consisting of phenyl, 3-phenyl, 5-phenyl, 4-chlorophenyl, 3-hydroxyphenyl, 3-(2-methylphenyl), 3-(3-aminophenyl), 2-pyridyl, 3-pyridyl, 3-(3-pyridyl), 4-pyridyl, 3-(3-thienyl), 3,5-di(trifluoromethyl)phenyl, 1-pyrrolidinyl, 2-furyl, 1-naphthyl, 2-thienyl, 1-imidazolyl, 2-benzimidazolyl and 2-tetrahydrofuryl; and pharmaceutically acceptable salts thereof.


6. (Cancelled)

7. (Original) A compound as in Claim 4 selected from the group consisting of

N-phenyl-1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidineacetamide;

N-(2,4-difluorophenyl)-1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidineacetamide;
N-phenyl-4-[2-[(E)-2-(2-pyridinyl)ethenyl]benzoyl]-1-piperazineacetamide;
N-phenyl-4-[3-(2-pyridinylethynyl)benzoyl]-1-piperazineacetamide;
N-(4-hydroxyphenyl)-1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidineacetamide;
and pharmaceutically acceptable salts thereof.


8. (Previously Presented) A compound as in Claim 4 wherein of the formula



X is CH;

R² is selected from the group consisting of phenyl, 4-hydroxyphenyl, 2-fluorophenyl, 4-fluorophenyl, and 2,4-difluorophenyl;

L² is selected from the group consisting of 3-~~—~~, 4-



R^4 is selected from the group consisting of 2-pyridyl, 4-pyridyl, 4-pyrrolidinyl, 2-furyl, 1-naphthyl and 3,5-di(trifluoromethyl)phenyl; and pharmaceutically acceptable salts thereof.

9. (Original) A compound as in Claim 8 wherein X is CH; R^2 is phenyl; L^2 is 3-~~—~~; R^4 is 2-pyridyl and pharmaceutically acceptable salts thereof.

10. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.

11. (Canceled).

12. (Original) A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.

13. (Original) A method of treating a nervous system disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.

14. (Previously Presented) The method of Claim 13, wherein the nervous system disorder is selected from the group consisting of depression, dementia, schizophrenia, bipolar disorders, anxiety, emesis, acute pain, neuropathic pain, itching, migraine and movement disorders.

15. (Original) A method of treating nervous system a disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the composition of Claim 10.

16. (Original) A method of treating a nervous system disorder selected from the group consisting of depression and anxiety in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 1.

17. (Original) A method of treating a nervous system disorder selected from the group consisting of depression and anxiety in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of Claim 10.

18. (Original) A method of treating a nervous system disorder selected from the group consisting of depression and anxiety in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of Claim 9.

19. (New) The compound of claim 1 wherein R⁴ is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-hydroxyphenyl, 2-methylphenyl, 3-aminophenyl, 3-thienyl, 3,5-di(trifluoromethyl)phenyl, 4-methoxyphenyl, 4-chlorophenyl, 2-thienyl, 2-furyl, 1-pyrrolidinyl, 1-imidazolyl, 2-benzimidazolyl, naphthyl and 2-tetrahydrofuryl.

20. (New) The compound of claim 1 wherein R⁴ is selected from the group consisting of phenyl, 3-phenyl, 5-phenyl, 4-chlorophenyl, 3-hydroxyphenyl, 3-(2-methylphenyl), 3-(3-aminophenyl), 2-pyridyl, 3-pyridyl, 3-(3-pyridyl), 4-pyridyl, 3-(3-thienyl), 3,5-di(trifluoromethyl)phenyl, 1-pyrrolidinyl, 2-furyl, 1-naphthyl, 2-thienyl, 1-imidazolyl, 2-benzimidazolyl and 2-tetrahydrofuryl.